Educational materials for healthcare professionals
Find educational materials on therapeutic products and cell, tissue or gene therapy products (CTGTP) intended for healthcare professionals or directed at their patients.
Last updated 19 May 2026
Overview
The educational materials listed below highlight specific safety concerns associated with the use of selected therapeutic products and CTGTP, and provide advice on the actions required to optimise the safe and effective use of these products.
Physician Educational Material (PEM): Intended for use by healthcare professionals in conjunction with the approved Singapore package insert. The PEM highlights safety concerns associated with the product and their risk mitigation measures e.g. selection of the appropriate patient group, close adherence to the recommended dosing information, close monitoring for early signs of adverse events that could require therapy modification.
Patient Medication Guide (PMG) and Patient Alert Card (PAC): Intended for dissemination by healthcare professionals to their patients or patients’ caregivers. The PMG and PAC provide important information for patients and their caregivers regarding the use of the product e.g. self-monitoring for early signs and symptoms of adverse events, when to seek prompt medical attention.
Only HSA-approved educational materials are listed below. These materials are published with the agreement of the company responsible for producing them, and are not intended to replace medical advice offered by healthcare professionals.
For electronic package inserts accessed from QR codes printed on the educational materials, there may be a time lag in the publishing of the latest approved package inserts after revisions are approved by HSA. Healthcare professionals should refer to HSA's website for the latest approved package insert for the product.
Search by brand name or active ingredient using the “Find” tool on your browser
Active ingredient(s) | Brand name | Company | Educational material(s) |
|---|---|---|---|
Ambrisentan | Volibris | GlaxoSmithKline Pte Ltd | |
Apixaban | Eliquis | Pfizer Private Limited | |
Apixaban | Apigat | Natco Pharma Asia Pte Ltd | |
Apixaban | Hemapix | Sandoz Singapore Pte Ltd | Hemapix PAC Material will be available soon |
Atezolizumab | Tecentriq | Roche Singapore Pte Ltd | |
Avelumab | Bavencio | Merck Pte Ltd | |
Axicabtagene ciloleucel | Yescarta | Gilead Sciences Singapore Pte Ltd | |
Bosentan | Proart | Ranbaxy (Malaysia) Sdn Bhd | |
Brexucabtagene autoleucel | Tecartus | Gilead Sciences Singapore Pte Ltd | |
Dabigatran | Pradaxa | Boehringer Ingelheim Singapore Pte Ltd | |
Dabigatran | Leaxolar | Lotus International Pte Ltd | |
Daratumumab | Darzalex | Johnson & Johnson International (Singapore) Pte Ltd | |
Deferasirox | Jadenu | Novartis (Singapore) Pte Ltd | |
Deferasirox | Desroxia | Lotus International Pte Ltd | |
Deferasirox | Ferasiro | Goldplus Universal Pte Ltd | |
Donanemab | Lormalzi | DKSH Singapore Pte Ltd | |
Dostarlimab | Jemperli | GlaxoSmithKline Pte Ltd | |
Durvalumab | Imfinzi | AstraZeneca Singapore Pte Ltd | |
Eculizumab | Soliris | AstraZeneca Singapore Pte Ltd | |
Edoxaban | Lixiana | A. Menarini Singapore Pte Ltd | |
Elranatamab | Elrexfio | Pfizer Private Limited | |
Emicizumab | Hemlibra | Roche Singapore Pte Ltd | |
Epcoritamab | Epkinly | Abbvie Pte Ltd | |
Esketamine | Spravato | Johnson & Johnson International (Singapore) Pte Ltd | |
Etranacogene dezaparvovec | Hemgenix | CSL Behring Pte Ltd | |
Etrasimod | Velsipity | Everest Medicines (Singapore) Pte Ltd | |
Fingolimod | Gilenya | Novartis (Singapore) Pte Ltd | |
Fingolimod | Fincord | Accord Healthcare Private Limited | |
Gilteritinib | Xospata | Astellas Pharma Singapore Pte Ltd | |
Glofitamab | Columvi | Roche Singapore Pte Ltd | |
Ipilimumab | Yervoy | Bristol-Myers Squibb (Singapore) Pte Ltd | |
Iptacopan | Fabhalta | Novartis (Singapore) Pte Ltd | |
Isatuximab | Sarclisa | Sanofi-aventis Singapore Pte Ltd | |
Ivosidenib | Tibsovo | Servier (S) Pte Ltd | |
Lecanemab | Leqembi | Eisai (Singapore) Pte Ltd | |
Lenalidomide | Revlimid | Bristol-Myers Squibb (Singapore) Pte Ltd | |
Lenalidomide | Leavdo | Pharm-D Singapore Private Limited | |
Lenalidomide | Lenalidomide Grindeks | Goldplus Universal Pte Ltd | |
Lenalidomide | Lenalidomide-Teva | Teva Pharmaceutical Investments Singapore Pte Ltd | |
Lenalidomide | Lenangio | Zyfas Pharma Pte Ltd | |
Lenalidomide | Lenli | Lotus International Pte Ltd | |
Lenalidomide | Linadex | Hetero Singapore Pte Ltd | |
Lenalidomide | Myolid | DKSH Singapore Pte Ltd | |
Leuprorelin | Eligard | DCH Auriga Singapore | |
Macitentan | Opsumit | Johnson & Johnson International (Singapore) Pte Ltd |
|
Macitentan, Tadalafil | Opsynvi | Johnson & Johnson International (Singapore) Pte Ltd |
|
Mavacamten | Camzyos | Bristol-Myers Squibb (Singapore) Pte Ltd | |
Mosunetuzumab | Lunsumio | Roche Singapore Pte Ltd | |
Natalizumab | Tysabri | Eisai (Singapore) Pte Ltd | |
Nivolumab | Opdivo | Bristol-Myers Squibb (Singapore) Pte Ltd | |
Nivolumab, Relatlimab | Opdualag | Bristol-Myers Squibb (Singapore) Pte Ltd | |
Onasemnogene abeparvovec | Zolgensma | Novartis (Singapore) Pte Ltd | |
Pembrolizumab | Keytruda | MSD Pharma (Singapore) Pte Ltd | |
Pomalidomide | Pomalyst | Bristol-Myers Squibb (Singapore) Pte Ltd | |
Pomalidomide | Pomagen | Lotus International Pte Ltd | |
Ravulizumab | Ultomiris | AstraZeneca Singapore Pte Ltd | |
Rivaroxaban | Xarelto | Bayer (South East Asia) Pte Ltd | |
Rivaroxaban | Estaelto | Wellesta Healthcare (Singapore) Pte Ltd | |
Rivaroxaban | Invarox | Intega Pte Ltd | |
Rivaroxaban | Rivaroxaban-Teva | Teva Pharmaceutical Investments Singapore Pte Ltd | |
Rivaroxaban | Rivason | Alma-A Pte Ltd | |
Rivaroxaban | Rivoban | Chemkraft Pte Ltd | |
Rivaroxaban | Xabarem | Goldplus Universal Pte Ltd | Xabarem PAC Material will be available soon |
Rivaroxaban | Zyroxaban | Apex Pharma Marketing Pte Ltd | |
Serplulimab | Zerpidio | Innogene Kalbiotech Pte Ltd | |
Siponimod | Mayzent | Novartis (Singapore) Pte Ltd | |
Spheroids of human autologous matrix-associated chondrocytes | SpheChon | ReLive Biotechnologies Pte Ltd | |
Tagraxofusp | Elzonris | A. Menarini Singapore Pte Ltd | |
Talquetamab | Talvey | Johnson & Johnson International (Singapore) Pte Ltd |
|
Tarlatamab | Imdelltra | Amgen Biotechnology Singapore Pte Ltd | |
Teclistamab | Tecvayli | Johnson & Johnson International (Singapore) Pte Ltd | |
Teprotumumab | Tepezza | Amgen Biotechnology Singapore Pte Ltd | Tepezza PEM Tepezza PMG Materials will be available soon |
Thalidomide | Domide | Pharm-D Singapore Private Limited | |
Tisagenlecleucel | Kymriah | Novartis (Singapore) Pte Ltd | |
Tislelizumab | Tevimbra | BeOne Medicines Singapore Pte Ltd | |
Tolvaptan | Jinarc | Otsuka Pharmaceuticals (Singapore) Pte Ltd | |
Toripalimab | Loqtorzi | TA Biosciences Pte Ltd | |
Tremelimumab | Imjudo | AstraZeneca Singapore Pte Ltd | |
Voretigene neparvovec | Luxturna | Novartis (Singapore) Pte Ltd | Note: Audio version of the PMG and PAC are available online. Please refer to the educational materials for the weblink. |